Adverum Biotechnologies

Adverum Biotechnologies is a Redwood City-based public biotech company pioneering gene therapy for debilitating ocular diseases. Its lead program, ixoberogene soroparvovec (ADVM-022), is an intravitreally administered AAV gene therapy designed to provide durable, continuous anti-VEGF treatment for wet AMD from a single injection—potentially eliminating the need for repeated monthly injections. The company reported positive preliminary results from the Phase 2 LUNA trial in 2024, demonstrating robust efficacy and a differentiated safety profile at the selected 6E10 vg/eye dose. Adverum is positioning ADVM-022 as a convenient in-office treatment that could dramatically reduce treatment burden for patients and healthcare systems while competing in a multi-billion-dollar retinal disease market.

Proprietary AAV.7m8 capsid engineered for efficient retinal transduction via intravitreal injection, delivering a codon-optimized aflibercept transgene for sustained intraocular anti-VEGF expression from a single in-office administration.

Adverum's most direct comparator is 4D Molecular Therapeutics (4D-150), which also uses an intravitreally delivered AAV gene therapy for wet AMD. REGENXBIO/AbbVie's ABBV-RGX-314 is further ahead in Phase 3 but requires subretinal surgical delivery, which Adverum positions as a competitive disadvantage versus its in-office injection approach. Extended-duration biologics including Roche's Vabysmo (up to 16-20 weeks) and Regeneron's high-dose Eylea HD raise the efficacy bar for gene therapy candidates to demonstrate meaningful improvement over the evolving standard of care.